vialroom

#retatrutide 2024-07-07

Sunday32 messages6 participantstimes are UTC
Highlights from this day
  • slow.taper — stopped for 15 months and restarted at half my old dose, the ramp was easier second time 18:15
  • pinch_not_stretch — is there any long term safety data at all or is it phase 2 and hope 19:29
  • ring_size_down — PeptideMeter came back 99.2 on one lot and 98.1 on the next from the same FGP, both fine 21:51
RS

i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps

anyone reconstituting 20 vials to 10 so the steps come out smaller

no long term data

right so my resting rate went up 5 bpm in the first month and came back most of the way by month 2

PN

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me, we shall see

smaller steps here

the phase 2 weight result was larger than what the earlier agonists reported, in a smaller shorter trial

ST

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

TS

triple agonist, GLP-1 and GIP and glucagon. the glucagon arm is the part with no long history, from memory

TS

sat at 15 for 4 months rather than climbing and it kept working, so i never went up

ST

stopped for 15 months and restarted at half my old dose, the ramp was easier second time

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)

follow up reconstituted the 20 vial to 2mg/ml specifically so i could take 7.5 without measuring crumbs

FN

did the phase 2 result actually come in higher than the tirzepatide numbers

A1

does the glucagon arm explain the heart rate or is that unrelated

📉23
A1

triple agonist yeah

fridge-temps.csv
632 rows · not retained in the public archive
📉8

how slow is low and slow here, four weeks a step or longer

TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

PN

is there any long term safety data at all or is it phase 2 and hope

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.
A1

my resting heart rate is up about 4 bpm, did that settle for anyone

PN

unrelated but i said 8 months ago that my heart rate had settled and it has stayed settled since

RS

blood pressure stayed flat for me while heart rate moved, which i didnt expect, i think

RS

PeptideMeter came back 99.2 on one lot and 98.1 on the next from the same FGP, both fine